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1. Introduction 
A cell therapy is a clinical treatment including an ex vivo cell manipulation step. Such a 
therapeutical option began more than forty years ago and is now a worldwide reality. Many 
human cell-based clinical trials have been developed in every medicine’s field mostly to 
cure diseases where conventional treatments are inadequate. Even though there have been 
few completed trials and some conflicting results on their effectiveness have been reported, 
the full potential of cell-based treatments remains to be explored and investigated (Park et 
al., 2008). Moreover, public expectation for such novel therapies, especially for treating 
incurable and/or rare diseases, remains high. Nowadays each tissue of the human body, 
including foetal and embryonic ones, can become a reliable source for cell therapy (Mason & 
Dunnill, 2009). Cells isolated from a specific source can be used  also to cure every other 
tissue of the body and may be administered alone, in combination with biomaterials, 
scaffolds, cytokines and growth factors or can be genetically manipulated (gene therapy). 
Cell administrations can be local or systemic, singles or multiples. Treatments may be 
autologous or allogeneic (from living or cadaver donors). A cell preparation can be crucial 
for a treatment such as in bone marrow transplantation or otherwise it may be used as an 
adjuvant to improve clinical results like in regenerative medicine or to slow down the 
development of several chronic conditions. Cell effect after treatment can be via the ability 
to differentiate along several lineages or, as recently highlighted for stem cells, also via the 
capacity to release anti-inflammatory cytokines, growth factors and proteins, collectively 
known as paracrine factors, which may modulate the host microenvironment by stimulating 
endogenous stem cells recruitment, differentiation and angiogenesis, thus acting as real 
drugs (Yagi et al., 2010). Ex vivo cell manipulation protocols are different, depending on cell 
source, type, target, disease and Country regulations. Current European cell therapy laws 
classify manipulation types according to potentially associated risks. Cutting, grinding, 
shaping, centrifugation, soaking in antibiotic or antimicrobial solutions, sterilization, 
irradiation, cell separation, concentration or purification, filtering, lyophilization, freezing, 
cryopreservation and vitrification are considered “minimal manipulations”. On the other 
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hand, cell processing like induction to proliferation, non-homologous use (if cells or tissues 
are not intended to be used for the same essential functions in the recipient as in the donor) 
and association with scaffolds or medical devices are defined as “extensive” or “ 
substantial” manipulations. These new kind of extensively manipulated cell-based products 
are termed “medicinal product for advanced cell therapy” (see Regulation (European 
Commission [EC]) No 1394/2007 of the European Parliament and of the Council on 
advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation 
(EC) No 726/2004). The term “medicinal” is not only a definition, but, of course, holds  
specific technical and practical consequences entering these products in the “drug world”. 
In fact, pre-clinical and clinical data that are necessary to demonstrate their quality, safety 
and efficacy should be highly specific. Moreover, it is also mandatory that they have to be 
manufactured like medicinal products. To this end, it is primarily required to have a 
suitable environment built as a real pharmaceutical factory and working according to 
specific rules named Good Manufacturing Practices (GMPs). GMPs are worldwide 
guidelines for the management of manufacturing and quality control of pharmaceutical 
products. The Food and Drug Administration [FDA] enforces GMPs in the United States 
while the European Medicines Agency [EMA] in Europe (The Rules Governing Medicinal 
Products in the European Union, Volume 4-Guidelines for Good Manufacturing Practices 
for medicinal products for human and veterinary use, current Edition) where 
manufacturing must be authorised by the competent Agency of each Member State. Such a 
structure (also named “cell factory” or “cleanroom facility”) allows minimization of any 
contamination risk by means of standardization and continuous monitoring of specific 
parameters such as air filtration and ventilation, temperature, relative humidity, differential 
pressure, number of air particles and bacterial colony forming units. Besides the 
environmental monitoring, cell culture and reagents must be checked for the presence of 
bacterial and viral contamination, mycoplasma and endotoxins. Furthermore, standard 
operative procedures, personnel training and process traceability should be developed and 
performed. Extensively manipulated cells are generally thought to be elaborate and costly, 
especially due to GMPs requirements. However they ensure three main characteristics: 
safety, product consistency and manufacturing quality. Considering that many cell 
therapies are still in an early experimental phase and that several aspects are not completely 
understood, these characteristics may represent a real guarantee for safe, standardized and 
controlled treatments. To date, proposed employments for cell-based medicinal products are 
quite impressive (Mason & Manzotti, 2010). Fields of interest are musculoskeletal tissue 
regeneration, autoimmune disorders, myocardial infarction, gastrointestinal diseases, 
urogenital system disorders, nervous system diseases, wound healing, plastic surgery, 
organ transplantation, graft versus host disease (GvHD) and diabetes 
(www.ClinicalTrials.gov). There is tremendous scope for applying cell therapeutics in the 
musculoskeletal system (Nöth et al., 2010). Cells can be used to repair or regenerate injured 
or diseased tissues (cartilage, bones, tendons, ligaments, muscles, etc..), or to treat chronic 
conditions such as Osteoarthritis or Rheumatoid Arthritis. As most cell therapy treatments 
for musculoskeletal diseases are not life-threatening, safety is a key issue for any clinical 
application. 
1.1 Autologous chondrocyte implantation 
Hyaline articular cartilage is a highly specialized tissue derived from mesenchyme during 
embryonic development. It has the main function to protect the joint by distributing loads 
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and thus preventing potentially damaging stress on the sub-chondral bone. At the same 
time it provides a low-friction bearing surface to enable free movements. Chondrocytes, the 
only cell type of mature cartilage, secrete and deposit around themselves a characteristics 
matrix composed primarily of water, collagens (mainly collagen type II), proteoglycans 
(mainly aggrecan) and other non-collagenous proteins (Becerra et al., 2010). Articular 
cartilage lesions are common in the general population and more often anticipated in young 
and physically active people. Despite the tissue is susceptible to damage, it has limited 
capacity for regeneration and repair because of poor vascular supply and lack of an 
undifferentiated cell population capable of migrating and responding to the insult 
(O’Driscoll, 1998). If left untreated, cartilage injuries may lead to pain and loss of function 
and predispose individuals to osteoarthritis in later life and eventually to requirements for 
total joint replacement (arthroplasty). The need of hospital attention is associated with a 
significant impact on quality of life and represents a huge socioeconomic burden to society. 
There is no uniform approach to managing cartilage defects (Harris et al., 2010). In younger, 
active patients “biologic” solutions that prevent or slow down tissue degradation process 
should be preferred. These procedures can be classified as palliative (arthroscopic 
debridement), reparative (microfracture) and regenerative such as pertiosteum, 
perichondrium or osteochondral grafting and Autologous Chondrocyte Implantation (ACI). 
Conventional treatments by debridement or microfracture produced various outcomes since 
the resulting repaired tissue is fibrocartilage which lacks the appropriate biochemical and 
biomechanical properties of normal healthy tissue. Currently, arthroscopic debridement and 
microfracture are commonly used as first-line treatment for symptomatic focal chondral 
defects that are relatively small with minimal associated bone loss. Regenerative procedures 
including ACI can be used as second-line measures to repair chondral or osteochondral 
defects. ACI therapeutical approach was first used by a Swedish Group (Brittberg et al., 
1994) to treat full-thickness chondral defects of the knee and later applied to the ankle. The 
treatment is now suitable also for other joints such as hip. In the original procedure (first 
generation technique) small grafts of normal cartilage removed from non-weight bearing 
areas of the knee were treated in a proper laboratory. Individual chondrocytes were 
isolated, cultured in specific conditions, and, following a period of cellular division, 
retrieved for re-implantation. Cell suspension was then injected beneath a periosteal patch 
harvested from the proximal medial tibia and sutured to the defect. Clinical, radiological 
and histological results are available at 10 to 20 years after the implantation, suggesting that 
outcomes remain high, with relatively few complications (Peterson et al., 2010). First 
generation ACI revealed, however, several disadvantages, such as transplant hypertrophy, 
calcification, delamination, cell leakage in the articular environment and loss of phenotype 
due to previous monolayer expansion. Given these shortcomings, recent experimental and 
clinical research has been directed towards the development of second generation ACI 
procedures using suitable scaffolds which act as carriers for the implantable cells 
maintaining at the meantime phenotype stability (Iwasa et al., 2009). These engineered 
tissues are then cut to the correct size and shape of the defects directly in the operatory 
room. The scaffolds, which efficiently "mimic" the natural surroundings of cartilage cells, 
may have different origins (synthetic, natural), characteristics (fibers, gels, sponges, 
microspheres, etc.) and spatial organization (two- or three-dimensional). Third generation 
ACI uses three-dimensional (3D) matrices such as hyaluronic acid as scaffolds. The process 
of implantation in second and third generation techniques can also be performed 
arthroscopically or with a small incision. Recently, a new technique called ’Characterized 
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Chondrocyte Implantation’ (CCI) utilizes a selected chondrocyte population that expresses a 
marker profile that can predict cell ability to produce in vivo hyaline-like cartilage (Saris et 
al., 2008). Many Authors in the Literature have suggested ACI effectiveness also for second 
and third generation techniques and these procedures are now widely diffused and utilized 
all over the world for cartilage defects repair. However, besides good outcomes evaluations, 
there is still scepticism about the use of ACI, particularly for its clinical and cost 
effectiveness in comparison with other traditional treatments and for the steeper learning 
curve, at least compared with marrow-stimulating techniques (Vasiliadis & Wasiak, 2010). 
Different Literature revisions highlighted that there is still insufficient evidence to draw 
conclusions and that further trials with long-term follow up are required in order to clarify 
ACI clinical benefits.. 
1.2 Cell manipulation in autologous chondrocyte implantation: from research to 
cleanroom 
Cell manipulation for ACI is crucial step that have to be performed in compliance with 
GMPs in order to guarantee a safe, standardized and efficacious product to implant. In this 
perspective the development of a validated and a repeatable process becomes a key issue for 
this therapy. Chondrocytes can be easily isolated from articular cartilage tissue by 
enzymatic treatments and then cultured in different conditions like monolayer, bi/three-
dimension, chemical or mechanical stimulation or inhibition. Several chondrocyte culture 
systems that have been developed display a huge number of applications in the research 
field as attested by worldwide publications. In fact they represent models for cartilage 
investigation, which is essential for identifying the pathways of both normal development 
and pathological degeneration and inflammation of the tissue (Roseti et al., 2007). Recently, 
there has been a great deal of interest in the ex vivo development of hyaline cartilage that can 
be utilized for the regeneration of damaged or diseased tissue. The realization that 
chondrocytes may act as drugs having therapeutical effects in cartilage regeneration led to 
new responsibilities and roles for cell culture’s laboratory. ACI application required an 
integration work between clinicians and cell biology experts and it would not have been 
possible without the support of GMPs specialized laboratories or facilities. Obviously, 
clinical application of research models presents specific features of quality assurance which 
must be met. In particular, for cell cultures, a transfer technology step is required or, in other 
words, research protocols must be translated into GMPs’ ones. This involves taking into 
account not only the peculiar nature of cells and culture’s models, but also the mandatory 
compliance with current GMPs and all the specific cell therapy regulations. This chapter 
describes the transfer technology utilized to standardize the manufacturing of engineered 
chondrocyte-based products for applications in ACI. In particular, it focuses on the 
development and validation of a GMPs’ compliant manufacturing process and then of 
“consistent” chondrocyte-based medicinal products. The GMP facility performing the below 
described validation processes is located in a public Hospital in Italy. Therefore specific 
Italian and European rules have been followed.  
2. Development and validation of a GMPs compliant chondrocyte culture 
process suitable for clinical use 
Process validation is a pre-requisite to ensure consistent manufacture. Cell processing such 
as in ACI is a long lasting, articulated process. It comprises three main manipulation phases 
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before final product packaging and release: cell isolation, expansion, and seeding onto 
biomaterials. For a complete GMPs compliance it is required that each step is validated 
singularly. One important thing to consider and to perform before starting is a careful 
evaluation and subsequent choice of high quality raw materials to be used in the process. 
Once the choice has been taken, the entire validation should be performed using the same 
materials. Changes are allowed, but a re-validation step is required. 
2.1 The choice of raw materials 
This is a highly critical step since raw materials, such as culture reagents or plastic wares, 
become directly in contact with the cells during the process. Moreover other materials, like 
scaffolds or cell supports, can become an integral part of the medicinal products. Therefore, 
the choice for such materials should be geared towards products ensuring the highest 
quality provided by the market at the moment. First of all, the cell producing facility should 
attest the quality assurance level of each Company/Institution that intends to choose as 
supplier. This investigation termed “supplier qualification” is mandatory for a fully GMPs 
compliance and should be performed not only by examining the accreditations provided by 
the Company itself but also by on-site inspections. Hence, material’s full batch 
documentation/certification should be carefully evaluated to attest fulfilment with specific 
current regulations. For example, cell culture media sterility should be certified by specific 
analyses validated in compliance with current European Pharmacopoeia. In particular, it is 
required that these products are negative for aerobic, anaerobic bacteria, fungi and 
endotoxins. Documentation control is a delicate and important step, but not sufficient for 
entering materials into the process. In fact, each declared critical feature should  be cross-
checked by internal quality controls in the cell factory. Only after passing such internal 
controls, materials are considered adequate for the process and validation can start. An 
important point to consider for reagent choice is to avoid zoonosis risks. A recombinant 
origin should be preferred for enzymes such as Trypsin used for the rapid detachment of 
adherent cells, like chondrocytes, from the growth substrate and Collagenase type II utilized 
to digest cartilage and thus isolate cells. In this case users should control documentation also 
for recombinant source that must be clearly indicated. For animal origin products, like foetal 
bovine serum (FBS) as supplement in culture, high quality is mandatory. FBS should be free 
of microbial, mycoplasma and viral contaminations. More importantly,  it must be stated 
and certified  its origin from Bovine Spongiform Encephalopathy (BSE) free countries such 
as Australia and New Zealand. The country of processing should be indicated too, if 
different. The serum producing process should be described giving evidence to exclude any 
possibility from contamination with tissues that may harbour the BSE agent, such as the 
brain, spinal cord and distal ileum. If the final product encloses other components like 
scaffolds or biomaterials they should be appropriately characterised and evaluated for 
suitability for the intended use. Nowadays the market displays variability and availability of 
such materials. For application in cartilage regeneration they have to display several 
properties: biocompatibility, biodegradability and malleability to fit defects. Moreover they 
should be viscous and adhesive enough to allow chondrocyte trapping and fixation to the 
implantation site, respectively. Furthermore they have to guarantee cell viability, growth 
and phenotype stability (Iwasa et al., 2009). A special comment is earned to cartilage biopsy 
that is considered a critical raw material since it is the starting point for processing, or the 
cell source. Even if it is not the focus of this chapter, it is important to underline that 
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cartilage biopsy collection should be validated too in order to minimize microbial 
contamination, tissue amount and quality (to ensure a sufficient cell number) and possible 
impurities arising from fragments of the synovial membrane or bony tissue. 
2.2 Chondrocyte isolation method 
In the last years Researchers have developed several protocols with the aim to isolate 
chondrocytes from cartilage tissue. In general, they consisted of sequential enzymatic 
digestions that unbound cells from matrix entrapment. Although effective and repeatable, 
these methods revealed to be not always suitable for therapeutical applications. In 
particular, the use of animal origin enzymes and long lasting processing times revealed to 
be problematic. In fact, GMPs rules require both to avoid animal origin components that can 
be a source of zoonosis and to shorten product exposition times in order to minimize 
microbial contamination risks. The method traditionally used by our group for research 
comprises three sequential digestions including also animal origin reagents (Roseti et al., 
2007). We translated this protocol into clinics using recombinant origin enzymes, reducing 
enzyme number and manipulation times. 
2.2.1 Materials and methods 
Healthy cartilage samples were harvested from the femoral condyle of three multi-organ 
donors (age: 23-71 years). To isolate chondrocytes three different methods were used.  
A Method. Cartilage samples were minced with a scalpel and carefully washed with cell 
culture medium Dulbecco’s Modified Eagle’s Medium-GMP grade (DMEM) (Li StarFish, 
Carugate, Milano, Italia) supplemented with L-glutamine-GMP grade 4 mM (Li StarFish). 
The chondrocytes were then isolated by sequential enzymatic digestion: 30 minutes with 880 
U/mL hyaluronidase (Sigma, St Louis, MO, USA) (10 mL/gr cartilage); 1h with 26.5 U/mL 
pronase (Sigma) (10 mL/gr cartilage) and 45 minutes with 740 U/mL collagenase II (Sigma) 
(20 mL/gr cartilage) at 37 °C, 5% CO2 and humidified atmosphere. To block collagenase 
activity, DMEM supplemented with 10% Fetal Bovine Serum-Pharma grade (FBS) (Li 
StarFish) was added. The isolated chondrocytes were filtered by 100 and 70 μm sterile nylon 
mesh filters to remove cell raft and matrix debris. The filtrate was then centrifuged and the 
pellet washed twice. Viable staining assessed cell number and viability.  
B Method. After mincing cartilage samples as described above (method A), digestion was 
performed only with 740 U/mL collagenase II (Sigma) (20 mL/gr cartilage) for 24 h at 37 °C, 
5% CO2 and humidified atmosphere. Isolation was then carried out as already described.  
C Method. After mincing cartilage samples as described above (method A), digestion was 
performed only with 740 U/mL collagenase (Li StarFish) (20 mL/gr cartilage) for 24 h at 37 
°C, 5% CO2 and humidified atmosphere. Isolation was then carried out as already described.  
2.2.2 Results 
Comparison between the three methods, performed normalizing isolated cell number per 
cartilage gram, indicated C Method as the most efficient (Figure 1). 
2.2.3 Discussion 
C methods allowed to avoid animal origin enzymes, to reduce number of reagents (one 
enzyme instead of three) and manipulation times, giving at the same time the best yield 
results. Therefore, being the most GMP compliant, it was our choice as isolation method. 
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Fig. 1. Comparison of chondrocyte isolation methods. 
A Method: sequential incubations with animal origin enzymes; B Method: animal origin 
collagenase II digestion; C Method: recombinant origin collagenase II digestion. Comparison 
was performed  normalizing cell number per  cartilage gram. 
2.3 Chondrocyte monolayer expansion 
Sera are mixtures of components essential for cell proliferation. They contain growth factors, 
hormones, molecules promoting cell adhesion and propagation, minerals trace and proteins 
like transferrin and albumin. FBS is traditionally and successfully used for cell cultures, 
including chondrocytes. The use of bovine-derived regents in clinical applications carries 
potential risks of contamination, especially Bovine Spongiform Encephalopathy (BSE) and 
immune responses. To develop our process we evaluated an alternative solution such as the 
use of human serum. 
2.3.1 Materials and methods 
C Method isolated chondrocytes (see section 2.2.1) were cultured in DMEM-GMP grade (Li 
StarFish) supplemented with L-glutamine-GMP grade 4 mM (Li StarFish) and with 10% 
FBS-Pharma grade (Li StarFish) or 10% human serum (HS) until passage two (three weeks). 
At 70% confluence cells were passaged with 1:250 Trypsin-EDTA-GMP grade (Li StarFish) 
and cell number and viability were assessed by viable staining. A high quality, FBS certified 
to be free of BSE and microbial, mycoplasma and viral contamination was utilized. Human 
serum was supplied in a sterile bag containing plasma drawn from donors. Under sterile 
conditions, plasma was added with calcium gluconate (0.3 ml/10 ml plasma) to induce 
coagulation process. After about two hours, the obtained serum was aspirated avoiding 
clots, transferred in a new bag and stored at -20°C. 
2.3.2 Results 
At passage 2, 10% FBS growth was three-times higher than 10% HS one (Figure 2). 
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Fig. 2. Comparison of chondrocyte expansion methods. 10% FBS: expansion with 10%FBS; 
10% HS: expansion with 10% human serum. 
2.3.3 Discussion 
The use of FBS for cell therapy is still controversial. Although bovine origin, FBS batches 
display less variability than the human ones and seem to better enhance cell growth. A 
reduction batch variability facilitate process standardization thus ensuring products 
consistency and robustness. Cell growth enhancement allows to shorten manipulation times 
and to reduce microbial contamination risks as well as progression to senescence. For these 
reasons our choice was towards FBS. The use of a high quality one (see section 2.1) appeared 
a good compromise between growth and safety requirements. 
2.4 Cartilage engineered cultures 
Many studies in the Literature have documented that monolayer expanded chondrocytes 
lose their phenotype becoming fibroblast-like cells. This de-differentiation process starts in 
the very first passages and progressively increases with time in culture. However, as 
attested by a number of study, such a situation can be reverted back when the cells are set in 
specifically defined conditions. It is as well documented that when de-differentiated 
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chondrocytes are seeded onto a biomaterial this specific configuration is able to allow the re-
differentiation process to occur (Roseti et al., 2007). As already evidentiated, new ACI 
generations utilize different biomaterials as scaffolds onto which expanded chondrocytes 
can grow and re-acquire their original phenotype. The biomaterial used in our manipulation 
process is a matrix consisting of collagen without cross-linking or chemical additives 
(Chondro-Gide, Geistlich Surgery, Germany). It is sterilized by gamma irradiation and 
provided in three different formats (2x3 cm2, 3x4 cm2 and 4x5 cm2). The collagen is extracted 
from pig and purified to avoid immunological reaction risks. The membrane has a two-
dimensional structure: a porous layer allowing cell seeding and culture and compact one 
acting as a barrier to prevent cell loss in the articular cavity. At the time of implantation the 
membrane is placed with the porous layer facing cartilage defect and the compact one facing 
the joint. Pre-clinical studies demonstrated its biocompatibility, low antigenicity, 
hydrophilicity (due to collagen  fiber microstructure) and biodegradability. This membrane 
has already been used by other groups for ACI (Haddo et al., 2004). Based on their 
experience and on ours with other biomaterials we started to verify effectiveness of this 
biomaterial in allowing cell colonization. Due to problems related to FBS for clinical use, we 
cultured cartilage engineered constructs in medium without this reagent. 
2.4.1 Materials and methods 
Chondrocyte cultures were carried on in monolayer for three weeks, in the standard 
conditions described above (C Method for isolation; DMEM with FBS for expansion). After 
trypsinization pellets were re-suspended in DMEM without FBS. Chondrocytes were then 
seeded onto collagen membranes at concentration of 1x106 cells/cm2 surface. Cells were 
then let to adhere for 15 minutes and finally DMEM without FBS was added to cover the 
membranes. The loaded scaffolds were incubated at 37° C, 5% CO2, and humidified 
atmosphere for 7 days. Cartilage engineered constructs were included in OCT and frozen at 
-80° C until analysis. Frozen blocks were cut in 25  m cryostat slices and slides were 
thawed and fixed in 4% paraformaldeid (PFA) for 30 minutes at room temperature. The 
samples were then rehydrated in H2O for 10 min. Slides were incubated with hematoxylin 
for 1-2 minutes and, after 4 washes in distilled water, hematoxylin was activated under 
running water for 10 minutes. Slides were incubated with eosin for 5 minutes and washed 
four times in distilled water. After dehydration, slides were mounted with Entellan and 
stored at room temperature. Samples were analysed using a Zeiss Axioscope Microscope 
(Carl Zeiss, Oberkochen, Germany). 
2.4.2 Results 
Chondrocytes cultured on collagen-based membranes had a spherical appearance when 
observed by light microscopy (Figure 3) and were uniformly distributed among collagen 
fibers in the porous layer. 
2.4.3 Discussion 
Our data confirmed the ability of the collagen-based bilayer membranes that we intended to 
use in our process to allow cell colonization. The observed distribution pattern has been 
already evidentiated in other scaffolds displaying similar composition and structure (De 
Franceschi et al., 2005). Interestingly, FBS absence did not compromise viability and 
colonization ability. 
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Fig. 3. Hematoxylin and eosin staining of porous layer in cartilage engineered tissues (40X). 
Spatial cell distribution is homogeneous among collagen fibers. The image is from one 
representative engineered tissue. Collagen fibers are indicated by black arrows. 
3. Final products validation: identification of defined “specifications” 
Final products of this GMPs manipulation model consist of engineered tissues derived from 
the combination of chondrocytes and bi-layer scaffold membranes. Validation is a GMPs 
requirement aimed at standardizing and thus defining final product peculiar features, 
technically named “product specifications”. They allow the identification of a specific 
product obtained with a specific process and intended for a specific clinical use. Once 
defined, specifications cannot be changed. Products displaying even one different feature 
has to be considered “other” and cannot be released for the intended clinical use. To change 
product specifications a new re-validation process has to be performed. The first validation 
to achieve for a cell-based product is sterility. It is aimed at defining absence of aerobic and 
anaerobic bacteria, fungi, mycoplasma and endotoxins by means of specific analytical 
methods. It has to be underlined that it also mandatory that these analytical methods have 
been upstream validated in compliance with current European Pharmacopoeia and GMPs. 
Besides sterility, that is not the focus of the  current chapter, the other specifications needed 
for cell-based products are: viability, potency, purity, yield and stability. To perform final 
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product validation we utilized the same cells and protocols as for process validation and 
analyses were performed onto the obtained cartilage engineered tissues. 
3.1 Viability 
In the Literature there are many methods for viability evaluation. Difficulties for analysis 
arise when cells are entrapped into a matrix or a scaffold, like in our process. In this case 
there is a real risk to underestimate the results. The Authors had already faced with this 
problem when managing other types of chondrocyte-scaffold constructs (Roseti el al., 
2007). In that occasions they were able to standardize a feasible method also applied in 
this model. 
3.1.1 Materials and methods 
Three engineered tissues -i.e. chondrocytes and collagen-based membranes (see section 
2.4.1)- and named Case 1, Case 2 and Case 3 were analysed. Cell viability was determined 
at the seeding onto the biomaterial (Day 0) and after 7 and 14 days in culture by 3-(4,5-
dimetiltiazolo-methyl)-2.5-difeniltetrazolio bromide (MTT) (Sigma)-mitochondrial 
reduction method, based on Mosmann original protocol (Denizot & Lang, 1986). Briefly, 
engineered constructs were transferred to 35x10 mm Petri dishes, added with 1 ml of a 
solution of 1 mg/ml MTT in PBS 1X and incubated for 3 hours. The membranes were then 
transferred in Eppendorf tubes and added with 1 ml of extraction solution consisting of 
0.01N HCl in isopropanol. The membranes, still contained in the Eppendorf tubes were 
then shaken and centrifuged at 14,000 rpm for 5 min to allow complete solubilisation of 
formazan. Finally, supernatant absorbance was read at 570 nm using a Beckman 
spectrophotometer.  
3.1.2 Results 
MTT testing, which is directly related to chondrocyte activity, showed slight increased 
values until day 7 for Case 1 and 2 and then a plateau maintained until day 14. Case 3 
chondrocytes did not show increased values, but immediately reached a plateau (Figure 4).  
3.1.3 Discussion 
The engineered constructs showed slight or no chondrocyte growth. These results are in 
contrast with the ones obtained with other biomaterials (Roseti et al., 2007) that highlighted 
a cell proliferation increase by time. We believe  that this is to be due to FBS deprivation 
that, however, allowed viability maintenance until day 14. The choice to use FBS only for the 
monolayer expansion phase where we demonstrated its efficacy in favouring cell growth 
(see section 2.3) and not for the engineered tissues represents for the Authors a good 
compromise to guarantee a safer therapy. 
3.2 Potency 
For chondrocyte-based products potency can be defined as cartilage forming capacity 
(Reflection paper on in-vitro cultured chondrocyte containing products for cartilage repair of 
the knee. Final. London, 08 April 2010 EMA/CAT/CPWP/568181/2009 Committee for 
Advanced Therapies [CAT], 2010). Therefore, to investigate if the final products displayed 
cartilage features we evaluated the presence of collagen type II and aggrecan, that are main 
recognized markers of this tissue (Becerra et al., 2010). 
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Fig. 4. MTT testing on engineered tissues (chondrocytes and collagen-based membranes) 
indicated as Case 1, 2 and 3. Samples were analysed after 0, 7 and 14 days in culture. Data 
are expressed as optical density at 570 nm. 
3.2.1 Materials and methods 
Tree engineered tissues -i.e. chondrocytes and collagen-based membranes (see section 2.4.1)- 
were embedded in OCT, snap-frozen in liquid nitrogen, cut into 25 m sections, air-dried 
and stored at -20 °C until use. These slides were transferred at room temperature, air-dried 
for 20 minutes and fixed in 4% PFA at room temperature for 20 minutes. The following 
primary antibodies were used: mouse anti-human collagen type II monoclonal antibody and 
mouse anti-human proteoglycans (Chemicon International Temecula, CA, USA). Air-dried 
fixed samples were rehydrated. Slides for collagen type II determinations were treated with 
0.1 % hyaluronidase (Sigma) in Phosphate Buffered Saline (PBS) at 37°C for 5 minutes for 
epitope unmasking; those for proteoglycans with chondroitinase ABC (Sigma) in Tris-HCl 
pH=8 for 30 minutes at room temperature. The slides were then incubated with the primary 
antibodies diluted 1:40 (collagen type II) or 1:50 (proteoglycans) in 0.04M Trizma Base Saline 
(TBS) pH 7.6 containing 1% BSA and 0.1 % Triton X-100 for 1 hour at room temperature. 
After washes in PBS with the addition of 1% BSA, the slides were incubated with 
biotinylated immunoglobulins specific for various animal species (BioGenex, San Ramon, 
CA, USA) for 20 minutes at room temperature. Then samples were incubated with a 
phosphatase-labeled streptavidin (BioGenex) for 20 minutes at room temperature, and after 
washes the reactions were developed using fast red substrate (BioGenex). Negative controls 
were performed by omitting the primary antibody. Slides were counterstained with 
hematoxylin and mounted in glycerol gel. All the samples were analysed using a Zeiss 
Axioscope Microscope (Carl Zeiss). 
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3.2.2 Results 
The engineered tissues revealed to be able to re-express specific cartilage markers. In 
particular, collagen type II immuno-staining revealed the presence of homogeneously 
diffused positive cell clusters (Figure 5) while proteoglycans appeared to be distributed in 
the extra-cellular matrix (Figure 6). 
3.2.3 Discussion 
This potency validation allowed to define an identity for our products, as specifically 
required by chondrocyte-based medicinal products guidance. It has to be mentioned that, as 
evidentiated in the Literature (Saris et al., 2008), one limitation of this system could be the 
inability to quantify results thus avoiding product good quality ranking. The Authors, on 
the other hand, suggest that such a quantification could not be really indicative of product 
quality or positive outcome in patients since there is still not complete evidence of a direct 
correlation between these features and because of documented patients variability in terms 
of basal values of cell number and cartilage markers expression. 
 
 
Fig. 5. Collagen type II immuno-staining on engineered constructs (80X).The image from 
one representative sample shows that the protein is uniformly distributed and mainly 
located inside the cells or in the peri-cellular matrix. Staining was developed using fast red 
substrate (red is positive stain). Biomaterial fibers are indicated by arrows.  
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3.3 Purity 
Purity is typically required for drugs. For advanced cell therapy medicinal products it 
means elimination or decrease of undesired cells. The unique type of cells in cartilage is 
chondrocyte. However cartilage biopsy should carry possible contaminants arising from 
fragments of the synovial membrane or from bone. These contaminants could be maintained 
during culture and thus become a part of the final products. To minimize these risks we 
standardized biopsy collection (data not shown) and developed a chondrocyte-specific 
culture method. Nevertheless, to be fully compliant with GMPs, we had to give evidence 
that our final products were free of cell contaminants. Therefore we analyzed the engineered 
tissues for the presence of two markers, one typical of fibroblasts (collagen type I) and one of 
bone phenotype (osteocalcin). 
 
 
Fig. 6. Proteoglycans immuno-staining on engineered constructs (40X). The image from one 
representative sample shows that proteoglycans were homogenously distributed 
throughout the whole extra-cellular matrix. Staining was developed using fast red substrate 
(red is positive stain).  
3.3.1 Materials and methods 
The same procedure described for potency validation was utilized (see Section 3.2.1). The 
following primary antibodies were used: mouse monoclonal anti-human collagen type I 
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(Chemicon International) diluted 1: 20 and Mouse anti-human osteocalcin (R&D Systems, 
Inc., Minneapolis, MN, U.S.A.) diluted 1:40. Slides for collagen type I determinations were 
treated with 0.1 % hyaluronidase (Sigma) in PBS at 37°C for 5 minutes for epitope 
unmasking. 
3.3.2 Results 
Engineered constructs were negative for collagen type I (Figure 7,) and osteocalcin (Figure 
8) immuno-staining both in the cells and in the newly synthesized matrix. 
 
 
Fig. 7. Collagen type I immuno-staining on engineered constructs (40X). The image from one 
representative sample shows that the protein is not present (no red areas were observed 
using fast red substrate). Biomaterial fibers are indicated by arrows. 
3.3.3 Discussion 
This validation is a further evidence of a defined identity of our products. Collagen type I 
absence is particularly meaningful: on one hand it indicates that synovial cells or tissues 
were not present at biopsy harvest and/or were not carried on with cultures; on the other 
hand it highlightes that chondrocytes within this biomaterial had reverted back to their 
original phenotype that was lost in monolayer culture. 
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3.4 Yield 
Yield can be defined as the number of cells obtained for each medicinal product. GMPs 
guidance requires yield validation, but in our experience this can be difficult to perform. In 
fact, yield is, more than the other specifications, subjected to variables that make quite 
problematic the required standardization. Intrinsic variability due to patient, cartilage 
quality or cell growth capacity do not completely depend from operators or process 
conditions and cannot be totally controlled. When we started our process we had yield 
validation data allowing a cell seeding onto the biomaterial of 1x106 cells per cm2. Lately, 
after more than 90 cultures, this initial specification has been replaced by a range of values: 
0.1 ÷ 1.1x106 cells per cm2. To accept and apply this new yield scale we had to re-validate the 
process and the products verifying that each value of the range was able to guarantee the 
development of viable and cartilage-like engineered tissues. 
 
 
Fig. 8. Osteocalcin immuno-staining on engineered constructs (20X). The image from one 
representative sample shows that the protein is not present (no red areas were observed 
using fast red substrate). Biomaterial fibers are indicated by arrows. Biomaterial fibers are 
indicated by arrows. 
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3.5 Stability 
Process validation ensures the manufacturing of standardized products displaying defined 
characteristics. But what happens after product release? A critical point is product stability 
over time: cell manufacturers should find the best storage conditions and times ensuring 
maintenance of products specifications. To define a product “shelf life” we performed a 
research in the literature and in the Companies/Institutions already producing this type of 
cells. Then we evaluated our products for each specification (see section 3) at release and at 
different times after. As expected, quality products started to decrease from the first day, but 
we found that after 4 days each specifications was preserved for at least 70% of the initial 
value. Therefore we chose that period of time as the shelf life of our products. 
4. Cryopreservation phase 
Chondrocyte manufacturing process may require a cryopreservation step in liquid nitrogen 
if, for any reason (technical or clinical) the ACI intervention is delayed or if a reservoir of 
cells is requested by the surgeon for other future treatments in the same patient. In both 
cases it is required that aliquots of cells are stored as “intermediate products” in proper and 
defined conditions. A validation step should be performed in order to demonstrate that the 
freezing/cryopreserving/thawing process does not alter all the cell properties needed for 
implantation. Considering our experience and literature data we decided to use dimethyl 
sulfoxide (DMSO) as cryo-protector agent.  
4.1 Materials and methods 
Three chondrocytes cultures (C Method isolation) at passage 1 were frozen and stored in 
liquid nitrogen gases. The freezing solution utilized was: DMEM-GMP grade (Li StarFish) 
supplemented with FBS-Pharma grade 40% and CryoSure-DMSO (Li StarFish) 10%. 
Samples were then thawed and cells seeded in medium supplemented with 20% FBS. After 
seven days, cultures returned to usual standard medium conditions (10% FBS). 
Chondrocytes were then seeded and cultured onto collagen biomaterial as described above. 
The final products were the checked for viability, yield, potency, purity and stability. 
4.2 Results 
In the three cultures analyzed the thawing process allowed a survival of 70, 92 and 70% of 
the cells, respectively. Cells were able to proliferate in monolayer and to reach a number 
sufficient for the seeding onto the collagen-based biomaterial. The final products revealed to 
be similar to the ones obtained without the cryopreservation step (data not shown). In 
particular, cells were viable, and expressing only typical cartilage markers.  
4.3 Discussion 
We developed a cryopreservation phase that can be included in ACI procedures without 
altering characteristics of final cartilage constructs. 
5. Conclusion  
The transfer technology described in this chapter allowed the development and validation 
of a safe, effective and robust GMPs compliant process articulated in different steps and 
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including a potential stand-by phase in liquid nitrogen. This process results in chondrocyte-
based medicinal products (a combination of cells and collagen-based membranes) with 
defined identity and stability that make them suitable for ACI therapeutical option in 
patients with articular cartilage damages. The Authors haver three main comments to 
disclose, based on this experience. The first is about the use of FBS in culture which, besides 
animal origin related problems, may imply immune responses in patients. We justify our 
choice to use FBS in monolayer conditions because it allowed a better cell growth 
standardization. However, since its potentially dangerous action could not be ignored, we 
decided to avoid FBS presence in the final products. This resolution was supported by 
validation data that were showing that the engineered tissues were cartilage-like also 
without this supplement. These results revealed to be in line with the literature and with 
data obtained by the Authors themselves with other chondrocyte constructs. Only the 
ability to grow inside the collagen-based biomaterial was importantly reduced, even if 
viability was consistently maintained. Therefore, considering implications due to FBS 
presence, our choice could be a good compromise for patient’s safety. The second comment 
is about the validation procedure itself. GMPs Guidance gives strict indication on how to 
carry on process and product validation thus minimizing contamination risks and variable 
elements. However such a standardization could be difficult to apply for cells. It is known 
that cell characteristics in culture are labile and subjected to modulation due non only to 
culture conditions (times, culture media, supplements an scaffolds) but also to patients (age, 
gender and pathology). In particular, quantification of some cell properties can become 
really hard to perform, thus hampering standardization. Therefore validation of a cell-based 
medicinal product, should mediate between the required “drug rules” and the intrinsic well 
known cell biological variability that is impossible to eliminate. The last comment is a 
consideration that cell therapy for cartilage regeneration is under vast exploration and there 
are now emerging other possibilities as well as improvement in this application. Allogeneic 
implantation, unexpanded chondrocytes, cell combination with new scaffolds and the use of 
pre-committed or undifferentiated precursors or mesenchymal stem cells from different 
sources are some examples of recent advancement in this field. In any case, Country 
legislation must be applied and our system can be also assumed as a valid model for the 
compliant GMPs development of other new products suitable for clinical purposes.  
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